Skip to main content
. 2017 Mar 21;21(9):1767–1780. doi: 10.1111/jcmm.13098

Figure 10.

Figure 10

Effect of tolvaptan on urinary excretion of AQP2. (A) Evaluation of urinary AQP2 in patient 1 affected by SIAD after 12‐h and 24‐h tolvaptan administration. (B) Effect of tolvaptan treatment on natraemia of patient 1. (C) Evaluation of urinary AQP2 in patient 2 affected by SIAD after 12‐h and 24‐h tolvaptan administration. (D) Effect of tolvaptan treatment on natraemia of patient 2.